Inflammatory Arthritis: Improving access through a Single National Formulary19 November 2026 For people living with rheumatoid arthritis, finding the right treatment can take time. They may need to try different medicines and manage side effects. They may also need to switch treatments if one stops working. Sometimes, the treatments a person can get depend on where they live. We have called this the ‘postcode lottery’ before. Could the NHS Single National Formulary (SNF) help change this? NRAS has jointly written to NHS England to ask for rheumatology to be included in the next phase of the SNF. The letter was drafted with the British Society for Rheumatology (BSR) and Arthritis UK. The Arthritis and Musculoskeletal Alliance (ARMA), the National Axial Spondyloarthritis Society (NASS) and Psoriasis UK also supported the letter. So, what is a Single National Formulary? Why do we think rheumatology should be included? And what could it mean for people with rheumatoid arthritis? What is the Single National Formulary (SNF)? A formulary is a list of medicines that local NHS organisations approve for their doctors and other health professionals to use when treating patients. At the moment, these decisions are made locally. This means the medicines available, and the rules for prescribing them, may depend on where someone lives. This is what we mean by a ‘postcode lottery’. The SNF aims to create one national approach to prescribing medicines. It would make the rules clearer and reduce differences between areas. The aim is to give people more equal access to medicines that are suitable for their medical needs. The first phase focuses on chronic heart failure, adult type 2 diabetes, asthma and eye care (ophthalmology). NHS England is considering which areas to include next. We think rheumatology should be top of the list. The postcode lottery in access to medicines in rheumatology Around 550,000 adults in England are living with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. For many, biologic and targeted therapies can make a significant difference to their symptoms and quality of life. Yet access to these treatments can vary depending on local prescribing policies and pathways. Research by Kaul and colleagues (2021) found that areas responsible for planning and paying for NHS care in England used different sets of rules for prescribing medicines. These are called prescribing pathways. The researchers identified 41 different pathways for rheumatoid arthritis, 29 for psoriatic arthritis and 25 for axial spondyloarthritis. The research also found that some local prescribing pathways limited how many advanced therapies a patient could try. To try another, the patient would need an individual funding request — a request for funding for their own treatment. Among the pathways studied, this limit applied to 54% of rheumatoid arthritis pathways, 59% of psoriatic arthritis pathways and 59% of axial spondyloarthritis pathways. These findings highlight how local arrangements can create added barriers for patients and clinicians, even where further treatment may be clinically appropriate. What could the SNF do for rheumatology? People with inflammatory arthritis need treatment that suits them. This is why rheumatology is a strong choice for the SNF. The range of biologic, biosimilar and targeted therapies is growing. Finding the right medicine may mean trying different treatments or switching between them. The choice depends on how well a medicine works, its side effects, other health conditions and the person’s circumstances. A national approach could help: Reduce unfair differences between areas: make the guidance on prescribing medicines clearer and more consistent across England. Local rules should not create unnecessary differences in the treatments people can get. Support doctors and other health professionals: make it easier to choose from a changing range of treatments. They would still have the freedom to choose treatment based on each person’s medical needs. Improve patient choice: help people get nationally recommended treatments when these are suitable for their medical needs. Where someone lives should not add extra barriers. Support shared decision-making: build on existing work such as RxInvolve, a pharmacist-designed tool that provides transparent medicines information and supports discussions between patients and clinicians. The aim is to make treatment options more consistent, not to limit them or take decisions away from health professionals. People respond differently to medicines. They may need to try several treatments before finding one that works for them. What happens next? Our letter asks NHS England to consider including rheumatology in the next phase of the SNF. It also asks NHS England to work with patients and the wider rheumatology community. The SNF will not solve every problem with access to medicines. On its own, it will not change how NHS services are planned and paid for, their funding, or how much care they can provide. But it could help with one important problem: different areas have different guidance on prescribing medicines. These differences can affect which treatments patients can get. Where you live should not be an extra barrier to getting a medicine. This applies when the medicine is nationally recommended and suitable for your medical needs. This is why NRAS, British Society for Rheumatology and Arthritis UK have come together to make the case for rheumatology. We hope to work with NHS England to help make this a reality for the half a million adults and young people living with inflammatory arthritis. Read the research: Kaul et al. (2021), Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery? Read the paper.